Skip to main content

Fiscal Wizard · Single-issue tearsheet

PAVM / Jun 21, 2026 Run #7356

PAVM

PAVmed Inc.

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Composite verdict

F 4.9 / 100
Bearish setup · Reversal 11 drivers · 5 gates blocking
  • Stochastic RSI
  • Fibonacci Retracement
  • Volume Climax
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 129th of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 18 signals100% Bear
Momentum Bearish 11Mean-reversion Neutral 41
  • Late-stage trendTrend signals have been live for 102 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -41%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

9.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Margin of Safety 0
Net Margin 75
OCF to Net Income 0
P/B 75
Free Cash Flow Yield 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Stochastic RSI, Fibonacci Retracement, Volume Climax); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Fibonacci Retracement 11
Stochastic RSI 11
Rate of Change 12

Risk Gates

5 blocking 8 caution

5 guards active, 22 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for PAVM.